253.28
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$253.91
Offen:
$257.11
24-Stunden-Volumen:
9.27M
Relative Volume:
1.09
Marktkapitalisierung:
$610.38B
Einnahmen:
$97.93B
Nettoeinkommen (Verlust:
$21.04B
KGV:
29.36
EPS:
8.6278
Netto-Cashflow:
$17.80B
1W Leistung:
-1.25%
1M Leistung:
-5.21%
6M Leistung:
+6.12%
1J Leistung:
+32.49%
Johnson Johnson Stock (JNJ) Company Profile
Firmenname
Johnson Johnson
Sektor
Telefon
732-524-2455
Adresse
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ
Compare JNJ vs LLY, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
JNJ
Johnson Johnson
|
253.28 | 610.38B | 97.93B | 21.04B | 17.80B | 8.6278 |
|
LLY
Lilly Eli Co
|
1,251.61 | 1.12T | 72.25B | 25.28B | 10.37B | 27.78 |
|
ABBV
Abbvie Inc
|
283.40 | 500.80B | 62.82B | 3.60B | 19.98B | 2.0274 |
|
MRK
Merck Co Inc
|
145.19 | 358.21B | 65.51B | 8.93B | 14.12B | 3.5532 |
|
NVS
Novartis Ag Adr
|
150.38 | 285.83B | 54.66B | 13.58B | 16.05B | 7.0171 |
Johnson Johnson Stock (JNJ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-02 | Fortgesetzt | UBS | Buy |
| 2026-05-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2026-04-08 | Fortgesetzt | TD Cowen | Buy |
| 2026-01-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-10-20 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-10-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-07-23 | Hochstufung | Erste Group | Hold → Buy |
| 2025-05-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-07-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-05-30 | Fortgesetzt | Goldman | Neutral |
| 2024-04-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2023-12-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-12-01 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Hold |
| 2023-05-30 | Fortgesetzt | Citigroup | Buy |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-14 | Bestätigt | BofA Securities | Neutral |
| 2022-06-22 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-05-23 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-03-16 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-15 | Bestätigt | Citigroup | Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-05-28 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-28 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-10-16 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2019-10-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2019-07-12 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-01-23 | Bestätigt | Barclays | Equal Weight |
| 2018-07-12 | Hochstufung | Goldman | Sell → Neutral |
| 2018-06-27 | Eingeleitet | Bernstein | Mkt Perform |
| 2018-04-23 | Bestätigt | Citigroup | Neutral |
| 2018-04-18 | Bestätigt | Stifel | Hold |
| 2018-01-24 | Bestätigt | Stifel | Hold |
| 2018-01-12 | Bestätigt | Wells Fargo | Outperform |
| 2018-01-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-10-18 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-18 | Bestätigt | Stifel | Hold |
Alle ansehen
Johnson Johnson Aktie (JNJ) Neueste Nachrichten
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research
Stock of the Day: Is this the Bottom for Johnson & Johnson? - TradingView
The Open Question Under Johnson & Johnson Stock’s Price - Trefis
Johnson & Johnson (JNJ) Stock Dropped, What Is Behind The Latest Attention? - Simply Wall Street
J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says - 24/7 Wall St.
JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges - Zacks Investment Research
Johnson & Johnson Reports Q3 2026 Results, Raises Full-Year Guidance - VisionMonday.com
Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff, as Q3 device sales disappoint - MassDevice
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research
UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research
Johnson & Johnson: Keep Calm And Hold On (NYSE:JNJ) - Seeking Alpha
J&J’s medtech business slows again in Q3 - MedTech Dive
Johnson & Johnson shares fall following earnings - CNBC
Why Johnson & Johnson Stock Dropped Today - The Motley Fool
Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth - Morningstar
Why Johnson & Johnson Stock Dropped Today - Yahoo Finance
Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit - Yahoo Finance
Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading - The Motley Fool
What Johnson & Johnson (JNJ) Said on Its Q3 Earnings Call - Yahoo Finance
J&J’s new pharma chief expects Icotyde’s psoriasis launch momentum to repeat across indications - Fierce Pharma
Small-Business Optimism Dips in September - Zacks Investment Research
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
Mixed Pre-Markets Greet Fresh Q3 Earnings Reports - Zacks Investment Research
Johnson & Johnson (JNJ) Reports 5.9% Revenue Growth, Plans Busin - GuruFocus
Johnson & Johnson (JNJ) Q3 FY2026 earnings call transcript - Yahoo Finance
Johnson & Johnson (JNJ) Raises 2026 Sales and EPS Guidance After Q3 Beat - GuruFocus
J&J's Tremfya posts forecast-topping quarter - FirstWord Pharma
Johnson & Johnson Q3 Profit Plunges, Lifts FY26 Outlook; Stock Drops - RTTNews
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 - BioSpace
Johnson & Johnson CFO Joseph Wolk on the company’s Q3 results - CNBC
Johnson & Johnson raises profit guidance in Q3 2026 earnings - Quartz
JOHNSON & JOHNSON ($JNJ) Releases Q3 2026 Earnings - Quiver Quantitative
J&J beats earnings estimates; Middle East conflict weighs on medical device sales - Reuters
J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027 - CNBC
Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates - Yahoo Finance
Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates - Zacks Investment Research
Johnson and Johnson Earnings Report | 2026 Q3 Infographic - Johnson & Johnson
J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business - WSJ
J&J beats earnings estimates; Middle East conflict weighs on medical device sales - Yahoo Finance
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance - Business Wire
Johnson & Johnson (JNJ) Stock May Be 28% Undervalued As TREMFYA Data Impresses - Yahoo Finance
Johnson & Johnson (JNJ) Stock May Be A Bargain Following New TREMFYA Trial Data - Simply Wall Street
Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell - The Motley Fool
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Johnson & Johnson earnings on deck: What to expect (JNJ:NYSE) - Seeking Alpha
Middle East Tensions Rattle Markets - Zacks Investment Research
Big Week of Data: Inflation & Q3 Earnings - Zacks Investment Research
Finanzdaten der Johnson Johnson-Aktie (JNJ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Johnson Johnson-Aktie (JNJ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schmid Timothy | EVP, WW Chair, MedTech |
Sep 02 '26 |
Sale |
274.74 |
33,597 |
9,230,440 |
25,447 |
| Schmid Timothy | Officer |
Sep 02 '26 |
Proposed Sale |
274.74 |
33,597 |
9,230,440 |
0 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine |
Aug 17 '26 |
Sale |
263.36 |
15,000 |
3,950,400 |
194,451 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine |
Aug 17 '26 |
Option Exercise |
115.67 |
15,000 |
1,735,050 |
209,451 |
| Taubert Jennifer L | Officer |
Aug 17 '26 |
Proposed Sale |
263.36 |
15,000 |
3,950,418 |
0 |
| Duato Joaquin | CEO and Chairman of the Board |
Aug 13 '26 |
Option Exercise |
115.67 |
123,291 |
14,261,070 |
399,258 |
| Duato Joaquin | CEO and Chairman of the Board |
Aug 13 '26 |
Sale |
261.17 |
123,291 |
32,199,927 |
275,967 |
| Duato Joaquin | Officer |
Aug 13 '26 |
Proposed Sale |
261.17 |
123,291 |
32,199,927 |
0 |
| Forminard Elizabeth | EVP, Chief Legal Officer |
Aug 06 '26 |
Option Exercise |
131.94 |
9,344 |
1,232,847 |
32,912 |
| Forminard Elizabeth | EVP, Chief Legal Officer |
Aug 06 '26 |
Sale |
257.00 |
15,918 |
4,090,960 |
16,994 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):